Precision Medicine Trends
News and analysis on diagnostic technologies and applications.
Precigen to Begin Phase II Study of PRGN-2009, Keytruda in HPV-Positive Cervical Cancer
The FDA granted the firm permission to study the off-the-shelf T-cell vaccine with the immune checkpoint inhibitor in pretreated metastatic HPV-positive cervical cancer patients.
RayzeBio Advances RYZ101 to Phase III Study in SSTR-Positive Neuroendocrine Tumors
The firm will compare its investigational radiopharmaceutical to standard therapies in patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors.
In particular, Black veterans seen through an on-site program at a Philadelphia VA medical center were nearly five times more likely to get tested than through a telemedicine consult.
Based on their success treating C. difficile, drugmakers are using different strategies to develop microbiome cancer therapies, including using genomics tools to home in on patient-specific strategies.
Cepheid Nabs CE-IVD Mark for Molecular NPM1 Mutation Test for AML Monitoring
The test quantifies mutant NPM1 mRNA transcripts in peripheral blood specimens from patients with acute myeloid leukemia.